THAP4

Across TCGA pan-cancer cohorts, THAP4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated THAP4 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher THAP4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated THAP4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where THAP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.513	0.310	.001	55	view →
CCRCC	OS	Median	All	1.000	0.888	.003	45	view →
LUAD	DFS	Tertile	All	0.784	0.993	.006	20	view →
GBM	DFS	Tertile	All	0.225	0.475	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

THAP4–PDAC (DFS)

Open the PDAC breakdown →